FREE UK Delivery over £45!



Babymoov Statement: FDA Guidelines on Sleep Positioners

Further to the recent news relating to re-issued advice from the US Food & Drug Administration (FDA) concerning sleep positioners, advice which originated following 12 deaths in the US between 1997 and 2010, whereby infants were placed on their side to sleep using a sleep positioning device¹, Babymoov’s Cosydream has been highlighted in several articles. The company has released the following statement:

We would like to assure customers that our award winning, paediatrician-approved Cosydream has never been involved in any incident connected with infant fatality. Nor does the Cosydream resemble the products that first gave rise to the FDA guidelines seven years ago.

Over 100,000 Cosydream units have been sold to satisfied customers worldwide since the product was first launched 4 years ago, during this time it has been met by wide acclaim.

The design of the Cosydream enables babies to sleep safely on their back in accordance with recommendations by the NHS. Using the Cosydream after feeds can help provide babies relief from symptoms of colic and reflux, it can also help prevent the onset of Plagiocephaly. The product is specifically designed for use from birth and, as per our guidelines, should not be used when baby is able to turn independently.

All our products comply with current regulations and the appropriate certification has been attained in relation to each of our baby sleep products.